136 related articles for article (PubMed ID: 9371233)
1. Synthesis of 5,6-dihydro-4-hydroxy-2-pyrones as HIV-1 protease inhibitors: the profound effect of polarity on antiviral activity.
Hagen SE; Prasad JV; Boyer FE; Domagala JM; Ellsworth EL; Gajda C; Hamilton HW; Markoski LJ; Steinbaugh BA; Tait BD; Lunney EA; Tummino PJ; Ferguson D; Hupe D; Nouhan C; Gracheck SJ; Saunders JM; VanderRoest S
J Med Chem; 1997 Nov; 40(23):3707-11. PubMed ID: 9371233
[No Abstract] [Full Text] [Related]
2. 4-hydroxy-5,6-dihydropyrones. 2. Potent non-peptide inhibitors of HIV protease.
Tait BD; Hagen S; Domagala J; Ellsworth EL; Gajda C; Hamilton HW; Prasad JV; Ferguson D; Graham N; Hupe D; Nouhan C; Tummino PJ; Humblet C; Lunney EA; Pavlovsky A; Rubin J; Gracheck SJ; Baldwin ET; Bhat TN; Erickson JW; Gulnik SV; Liu B
J Med Chem; 1997 Nov; 40(23):3781-92. PubMed ID: 9371244
[TBL] [Abstract][Full Text] [Related]
3. Structure-based design of HIV protease inhibitors: 5,6-dihydro-4-hydroxy-2-pyrones as effective, nonpeptidic inhibitors.
Thaisrivongs S; Romero DL; Tommasi RA; Janakiraman MN; Strohbach JW; Turner SR; Biles C; Morge RR; Johnson PD; Aristoff PA; Tomich PK; Lynn JC; Horng MM; Chong KT; Hinshaw RR; Howe WJ; Finzel BC; Watenpaugh KD
J Med Chem; 1996 Nov; 39(23):4630-42. PubMed ID: 8917652
[TBL] [Abstract][Full Text] [Related]
4. 4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters.
Hagen SE; Domagala J; Gajda C; Lovdahl M; Tait BD; Wise E; Holler T; Hupe D; Nouhan C; Urumov A; Zeikus G; Zeikus E; Lunney EA; Pavlovsky A; Gracheck SJ; Saunders J; VanderRoest S; Brodfuehrer J
J Med Chem; 2001 Jul; 44(14):2319-32. PubMed ID: 11428926
[TBL] [Abstract][Full Text] [Related]
5. Structure-based design of novel HIV protease inhibitors: sulfonamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent non-peptidic inhibitors.
Thaisrivongs S; Janakiraman MN; Chong KT; Tomich PK; Dolak LA; Turner SR; Strohbach JW; Lynn JC; Horng MM; Hinshaw RR; Watenpaugh KD
J Med Chem; 1996 Jun; 39(12):2400-10. PubMed ID: 8691434
[TBL] [Abstract][Full Text] [Related]
6. Nonsymmetrically substituted cyclic urea HIV protease inhibitors.
Wilkerson WW; Dax S; Cheatham WW
J Med Chem; 1997 Dec; 40(25):4079-88. PubMed ID: 9406598
[TBL] [Abstract][Full Text] [Related]
7. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease.
Kaldor SW; Kalish VJ; Davies JF; Shetty BV; Fritz JE; Appelt K; Burgess JA; Campanale KM; Chirgadze NY; Clawson DK; Dressman BA; Hatch SD; Khalil DA; Kosa MB; Lubbehusen PP; Muesing MA; Patick AK; Reich SH; Su KS; Tatlock JH
J Med Chem; 1997 Nov; 40(24):3979-85. PubMed ID: 9397180
[TBL] [Abstract][Full Text] [Related]
8. Nonpeptidic potent HIV-1 protease inhibitors: (4-hydroxy-6-phenyl-2-oxo-2H- pyran-3-yl)thiomethanes that span P1-P2' subsites in a unique mode of active site binding.
Prasad JV; Para KS; Tummino PJ; Ferguson D; McQuade TJ; Lunney EA; Rapundalo ST; Batley BL; Hingorani G; Domagala JM
J Med Chem; 1995 Mar; 38(6):898-905. PubMed ID: 7699705
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and HIV protease inhibitory activity of new 4-hydroxy-2-pyrone derivatives.
Lee YS; Kim SN; Lee YS; Lee JY; Lee CK; Kim HS; Park H
Arch Pharm (Weinheim); 2000 Oct; 333(10):319-22. PubMed ID: 11092133
[No Abstract] [Full Text] [Related]
10. Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors.
Skulnick HI; Johnson PD; Howe WJ; Tomich PK; Chong KT; Watenpaugh KD; Janakiraman MN; Dolak LA; McGrath JP; Lynn JC
J Med Chem; 1995 Dec; 38(26):4968-71. PubMed ID: 8544171
[No Abstract] [Full Text] [Related]
11. Non-peptidic HIV protease inhibitors: C2-symmetry-based design of bis-sulfonamide dihydropyrones.
Janakiraman MN; Watenpaugh KD; Tomich PK; Chong KT; Turner SR; Tommasi RA; Thaisrivongs S; Strohbach JW
Bioorg Med Chem Lett; 1998 May; 8(10):1237-42. PubMed ID: 9871742
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design of HIV protease inhibitors: 4-hydroxycoumarins and 4-hydroxy-2-pyrones as non-peptidic inhibitors.
Thaisrivongs S; Tomich PK; Watenpaugh KD; Chong KT; Howe WJ; Yang CP; Strohbach JW; Turner SR; McGrath JP; Bohanon MJ
J Med Chem; 1994 Sep; 37(20):3200-4. PubMed ID: 7932546
[No Abstract] [Full Text] [Related]
13. Nonpeptidic HIV protease inhibitors possessing excellent antiviral activities and therapeutic indices. PD 178390: a lead HIV protease inhibitor.
Prasad JV; Boyer FE; Domagala JM; Ellsworth EL; Gajda C; Hamilton HW; Hagen SE; Markoski LJ; Steinbaugh BA; Tait BD; Humblet C; Lunney EA; Pavlovsky A; Rubin JR; Ferguson D; Graham N; Holler T; Hupe D; Nouhan C; Tummino PJ; Urumov A; Zeikus E; Zeikus G; Gracheck SJ; Erickson JW
Bioorg Med Chem; 1999 Dec; 7(12):2775-800. PubMed ID: 10658583
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, antiviral activity, and bioavailability studies of gamma-lactam derived HIV protease inhibitors.
Hungate RW; Chen JL; Starbuck KE; Vacca JP; McDaniel SL; Levin RB; Dorsey BD; Guare JP; Holloway MK; Whitter W
Bioorg Med Chem; 1994 Sep; 2(9):859-79. PubMed ID: 7712123
[TBL] [Abstract][Full Text] [Related]
15. Nonpeptidic HIV protease inhibitors: 6-alkyl-5,6-dihydropyran-2-ones possessing a novel and achiral 3-(2-t-butyl-5-methyl-4-sulfamate)phenylthio moiety.
Vara Prasad JV; Markoski LJ; Boyer FE; Domagala JM; Ellsworth EL; Gajda C; Hagen SE; Tait BD; Lunney EA; Tummino PJ; Ferguson D; Holler T; Hupe D; Nouhan C; Gracheck SJ; VanderRoest S; Saunders J; Iyer K; Sinz M
Bioorg Med Chem Lett; 1999 Aug; 9(15):2217-22. PubMed ID: 10465549
[TBL] [Abstract][Full Text] [Related]
16. Cycloalkylpyranones and cycloalkyldihydropyrones as HIV protease inhibitors: exploring the impact of ring size on structure-activity relationships.
Romines KR; Morris JK; Howe WJ; Tomich PK; Horng MM; Chong KT; Hinshaw RR; Anderson DJ; Strohbach JW; Turner SR; Mizsak SA
J Med Chem; 1996 Sep; 39(20):4125-30. PubMed ID: 8831779
[TBL] [Abstract][Full Text] [Related]
17. Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class.
Turner SR; Strohbach JW; Tommasi RA; Aristoff PA; Johnson PD; Skulnick HI; Dolak LA; Seest EP; Tomich PK; Bohanon MJ; Horng MM; Lynn JC; Chong KT; Hinshaw RR; Watenpaugh KD; Janakiraman MN; Thaisrivongs S
J Med Chem; 1998 Aug; 41(18):3467-76. PubMed ID: 9719600
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and antiviral activity of new anti-HIV amprenavir bioisosteres.
Rocheblave L; Bihel F; De Michelis C; Priem G; Courcambeck J; Bonnet B; Chermann JC; Kraus JL
J Med Chem; 2002 Jul; 45(15):3321-4. PubMed ID: 12109915
[TBL] [Abstract][Full Text] [Related]
19. Discovery and clinical development of HIV-1 protease inhibitors.
Huff JR; Kahn J
Adv Protein Chem; 2001; 56():213-51. PubMed ID: 11329855
[No Abstract] [Full Text] [Related]
20. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor.
Poppe SM; Slade DE; Chong KT; Hinshaw RR; Pagano PJ; Markowitz M; Ho DD; Mo H; Gorman RR; Dueweke TJ; Thaisrivongs S; Tarpley WG
Antimicrob Agents Chemother; 1997 May; 41(5):1058-63. PubMed ID: 9145869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
